Page last updated: 2024-12-10

ganodermanontriol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ganodermanontriol: an antineoplastic agent; isolated from Ganoderma lucidum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID146156361
MeSH IDM0558146
PubMed CID3001811
CHEMBL ID1915763
CHEBI ID68858

Synonyms (16)

Synonym
106518-63-2
ganodermanontriol
lanosta-7,9(11)-dien-3-one, 24,25,26-trihydroxy-, (24s,25r)-
(5r,10s,13r,14r,17r)-4,4,10,13,14-pentamethyl-17-[(2r,5s,6r)-5,6,7-trihydroxy-6-methylheptan-2-yl]-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
6nb33mkr8f ,
chebi:68858 ,
bdbm50356923
CHEMBL1915763 ,
Q27137215
HY-N1506
CS-0017049
DTXSID10910025
26-hydroxyganodermanondiol
(24s,25r)-24,25,26-trihydroxylanosta-7,9(11)-dien-3-one
(5r,10s,13r,14r,17r)-4,4,10,13,14-pentamethyl-17-((2r,5s,6r)-5,6,7-trihydroxy-6-methylheptan-2-yl)-4,5,6,10,12,13,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
AKOS040733229
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)200.00000.00001.559910.0000AID630340
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)22.31000.00000.933210.0000AID630339
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinoic acid receptor RXR-alphaMus musculus (house mouse)EC50 (µMol)2.50000.04001.71805.0000AID629094
Bile acid receptorMus musculus (house mouse)EC50 (µMol)2.50000.15202.04315.0000AID629094
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaMus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID1235935Cytotoxicity against human PC3 cells by MTT method2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID630339Inhibition of AChE assessed as hydrolysis of acetylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum.
AID633518Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2011Journal of natural products, Nov-28, Volume: 74, Issue:11
Semisynthesis and biological evaluation of ganodermanontriol and its stereoisomeric triols.
AID779722Inhibition of alpha-glucosidase (unknown origin) using sucrose as substrate assessed as formation of glucose after 30 mins by glucose oxidase method2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Structure-activity relationships of lanostane-type triterpenoids from Ganoderma lingzhi as α-glucosidase inhibitors.
AID629057Agonist activity at FXR in human HepG2 cells assessed as inhibition of CYP7A1 mRNA expression at 50 uM for 6 hrs by RT-PCR relative to control2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID629058Antiinflammatory activity in human HUVEC cells assessed as inhibition of LPS-induced IL-8 mRNA expression at 5 uM for 10 mins measured after 4 hrs of LPS challenge by Q-PCR analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID629094Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID629093Antiinflammatory activity in human HUVEC cells assessed as inhibition of TNF-alpha-induced E-selectin mRNA expression at 5 uM for 10 mins measured after 4 hrs of LPS challenge by Q-PCR analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID1235933Inhibition of maltase in rat intestinal mucosa pre-incubated for 40 mins using maltose substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID1235931Inhibition of alpha-glucosidase in rat intestinal mucosa pre-incubated for 40 mins using p-nitrophenyl-alpha-D-glucopyranoside substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID630340Inhibition of BChE assessed as hydrolysis of butrylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum.
AID1235929Inhibition of pig liver microsomes HMG-CoA reductase incubated for 5 mins in using HMG-CoA and NADPH by colorimetric method2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID1313603Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs measured after 15 mins by Griess assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Lanostane triterpenoids from Ganoderma curtisii and their NO production inhibitory activities of LPS-induced microglia.
AID629059Antiinflammatory activity in human HUVEC cells assessed as inhibition of TNF-alpha-induced IL-8 mRNA expression at 5 uM for 10 mins measured after 4 hrs of LPS challenge by Q-PCR analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
AID1235932Inhibition of sucrase in rat intestinal mucosa pre-incubated for 40 mins using sucrose substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID711431Cytotoxicity against mouse LLC cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID711441Cytotoxicity against human HeLa cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID1313604Cytotoxicity against LPS-induced mouse BV2 cells assessed as cell viability after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Lanostane triterpenoids from Ganoderma curtisii and their NO production inhibitory activities of LPS-induced microglia.
AID633487Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2011Journal of natural products, Nov-28, Volume: 74, Issue:11
Semisynthesis and biological evaluation of ganodermanontriol and its stereoisomeric triols.
AID1235930Inhibition of Baker's yeast alpha-glucosidase2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID711428Cytotoxicity against mouse Meth-A cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID1845462Antiviral activity against DENV2 infected in human A549 cells at 25 uM incubated for 24 hrs by plaque assay relative to control2021Journal of natural products, 01-22, Volume: 84, Issue:1
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
AID1235934Cytotoxicity against human K562 cells by MTT method2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID629092Antiinflammatory activity in human HUVEC cells assessed as inhibition of LPS-induced E-selectin mRNA expression at 5 uM for 10 mins measured after 4 hrs of LPS challenge by Q-PCR analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (76.47)24.3611
2020's4 (23.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.66 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews2 (25.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]